Sodium O-ethyl dithiocarbonate

Endpoint summary

Key value for chemical safety assessment

Repeated dose toxicity: via oral route - systemic effects

Link to relevant study records

Reference

Endpoint:

sub-chronic toxicity: oral

Type of information:

experimental study

Adequacy of study:

supporting study

Reliability:

2 (reliable with restrictions)

Qualifier:

equivalent or similar to guideline

Guideline:

OECD Guideline 408 (Repeated Dose 90-Day Oral Toxicity Study in Rodents)

GLP compliance:

not specified

Limit test:

no

Species:

rat

Details on oral exposure:

4 months

Dose / conc.:

10 mg/kg bw (total dose)

Dose descriptor:

LOAEL

Effect level:

10 mg/kg bw/day (actual dose received)

Based on:

test mat.

Sex:

not specified

Basis for effect level:

clinical biochemistry

Critical effects observed:

yes

Lowest effective dose / conc.:

10 mg/kg bw (total dose)

System:

haematopoietic

Treatment related:

yes

Relevant for humans:

not specified

During administration effects observed from week 6 to week 7 of treatment were tachypnoea, cyanosis, lossof hair and dermatitis. Loss of weight and increase in blood sugar and cholesterolwere observed later. Convulsions and paralysis of the extremities were observed insome animals from week 9 of administration. Some animals died during theadministration

Conclusions:

Findings were included central nervous system, liver and spleen effects.

Endpoint conclusion

Endpoint conclusion:

adverse effect observed

Dose descriptor:

LOAEL

10 mg/kg bw/day

Study duration:

chronic

Species:

rat

Repeated dose toxicity: inhalation - systemic effects

Link to relevant study records

Reference

Endpoint:

short-term repeated dose toxicity: inhalation

Type of information:

experimental study

Adequacy of study:

supporting study

Study period:

30 days

Reliability:

2 (reliable with restrictions)

Rationale for reliability incl. deficiencies:

data from handbook or collection of data

Justification for type of information:

Data on related xanthate provided as supporting information

Qualifier:

equivalent or similar to guideline

Guideline:

OECD Guideline 412 (Subacute Inhalation Toxicity: 28-Day Study)

GLP compliance:

not specified

Limit test:

no

Species:

dog

Strain:

Beagle

Sex:

male

Route of administration:

inhalation: aerosol

Type of inhalation exposure:

whole body

Vehicle:

air

Analytical verification of doses or concentrations:

yes

Duration of treatment / exposure:

30-day

Frequency of treatment:

6 hrs daily, 5 days a week for a total of 20 exposures in 1 month

Dose / conc.:

100 mg/m³ air (nominal)

Dose / conc.:

800 mg/m³ air (nominal)

No. of animals per sex per dose:

2

Control animals:

yes

Observations and examinations performed and frequency:

Daily

Clinical biochemistry findings:

no effects observed

Urinalysis findings:

no effects observed

Dose descriptor:

LOEC

Effect level:

100 mg/m³ air (nominal)

Based on:

test mat.

Sex:

male

Basis for effect level:

other: Hepatotoxic effects

Critical effects observed:

not specified

Conclusions:

The results of this study indicate that potassium amyl xanthate has an adverse effect on the the liver in dogs. There were no treatment-related changes in the haematological or urinalysis values in any of the animals.

Endpoint conclusion

Endpoint conclusion:

adverse effect observed

Dose descriptor:

LOAEC

100 mg/m³

Study duration:

subacute

Species:

dog

Quality of whole database:

Inhalation of potassium amyl xanthate produces adverse effects in the livers of dogs.

Repeated dose toxicity: inhalation - local effects

Endpoint conclusion

Endpoint conclusion:

no adverse effect observed

Repeated dose toxicity: dermal - systemic effects

Endpoint conclusion

Endpoint conclusion:

no study available

Repeated dose toxicity: dermal - local effects

Endpoint conclusion

Endpoint conclusion:

no study available

Additional information

In the absence of reliable information, the data forpotassium amyl xanthate (CAS# 2720-73-2) may be used as a surrogate for sodium ethyl xanthate (CAS# 140-90-9).

The target sites for sodium ethyl xanthate, and other xanthates are the central nervous system, liver and kidneys. The adverse effects seen in the toxicity studies could be due to the xanthates (such as sodium ethyl xanthate), their decomposition products or a combination of both.

There is no human information available concerning reproductive toxicity for xanthates(, CHEMINFO ,2004, ,Chemical Profiles Created by CCOHS , www.ccohs.ca).

Repeated dose toxicity: via oral route - systemic effects (target organ) cardiovascular / hematological: other; neurologic: central nervous system

Repeated dose toxicity: inhalation - systemic effects (target organ) digestive: liver